Related Experiment Video

Updated: Sep 18, 2025

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

2.7K

Ubiquitination in cancer: mechanisms and therapeutic opportunities

Susi Zhu1,2,3,4,5, Xu Zhang1,2,3,4,5, Waner Liu1,2,3,4,5

  • 1Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.

Cancer Communications (London, England)
|June 19, 2025
PubMed

Insights

Ubiquitination regulates key cancer processes like metabolism and immunity. Targeting ubiquitination pathways, including E3 ligases and deubiquitinases, offers promising new cancer treatment strategies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Ubiquitination is a critical post-translational modification influencing tumor biology.
  • It regulates essential cellular processes including metabolism, cell death, and immune responses.
  • Interactions with other modifications are linked to cancer progression and therapeutic response.

Purpose of the Study:

  • To provide an overview of ubiquitination's influence on tumor biology.
  • To highlight roles in immune regulation and metabolism.
  • To summarize the clinical potential of targeting ubiquitination in cancer therapy.

Main Methods:

  • Literature review of recent advancements in ubiquitination research.
  • Analysis of ubiquitination's impact on tumorigenesis, progression, and the tumor microenvironment.
  • Exploration of therapeutic strategies targeting E3 ubiquitin ligases and deubiquitinases.

Main Results:

  • Ubiquitination significantly impacts cancer cell metabolism and immune evasion.
  • Its interplay with other post-translational modifications affects tumor development and treatment outcomes.
  • Targeting specific ubiquitination enzymes presents novel therapeutic avenues.

Conclusions:

  • Understanding ubiquitination mechanisms offers new diagnostic and treatment strategies for cancer.
  • Targeting E3 ubiquitin ligases and deubiquitinases shows significant clinical potential for cancer therapy.
  • Further research into ubiquitination pathways can lead to more effective cancer treatments.
Keywords:
Ubiquitinationcell deathmetabolismtherapeutic opportunitiestumor microenvironment

More Related Videos

In Vitro Ubiquitination and Deubiquitination Assays of Nucleosomal Histones11:36

In Vitro Ubiquitination and Deubiquitination Assays of Nucleosomal Histones

Published on: July 25, 2019

10.9K
Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations10:26

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations

Published on: November 7, 2019

5.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
7.4K
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K